Prucalopride is a dihydrobenzofurancarboxamide derivative from the benzofurane family that selectively stimulates 5-HT4 receptors and thus, it presents enterokinetic properties. The high selectivity of prucalopride allowed further development as it prevented the cardiac adverse reactions observed due to non-target effects of precedent therapies. Prucalopride...
Prucalopride is indicated for the treatment of chronic idiopathic constipation (CIC) in adults.
CIC is one of the most common chronic functional gastrointestinal disorders worldwide. The diagnosis of this agent is very hard and it can be confirmed if the patient experience at least two of the following:
...
Skåne University Hospital, Malmö, Sweden
Kasr Al Ainy Hospital, Cairo, Egypt
University of Passo Fundo, Passo Fundo, RS, Brazil
Department of Psychiatry, Warneford Hospital, University of Oxford, Oxford, Oxfordshire, United Kingdom
Pediatric & Adult Research Center, Kissimmee, Florida, United States
The University of Chicago Medical Center, Chicago, Illinois, United States
Cleveland Clinic, Cleveland, Ohio, United States
Faculty of Medicine, Prince of Songkla University, Songkhla, Thailand
University of Oxford, Oxford, United Kingdom
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.